Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

12.1K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

76.9K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
76.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing phage therapy with antidefense proteins acquired from the environment.

Frontiers in microbiology·2026
Same author

Intermolecular C─H···M (M = Fe and V) Interactions in Metalloporphyrins: A Combined Experimental and Computational Perspective.

Chemphyschem : a European journal of chemical physics and physical chemistry·2026
Same author

Zinc-Porphyrin Terephthalate-Based Metal-Organic Framework: Structural Insights and Functional Antibacterial Properties.

Chembiochem : a European journal of chemical biology·2026
Same author

Diversity of DNA viruses in the atmosphere of sub-Antarctic South Georgia.

Frontiers in microbiology·2026
Same author

Incorporation of Functional Proteins on Cellular Surfaces via Artificial Cell-Derived Vesicles (ACDVs) for Plasma Membrane Reprogramming.

Journal of the American Chemical Society·2026
Same author

Polymeric Lysosome-Targeting Chimeras (PolyTACs): Extracellular Targeted Protein Degradation without Co-Opting Lysosome-Targeting Receptors.

Journal of the American Chemical Society·2026

Related Experiment Video

Updated: May 23, 2025

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.2K

Dual-Action-Only PROTACs.

Ranit Dutta1,2, Anirudh Devarajan1,2, Amelia Talluri1

  • 1Department of Chemistry, University of Massachusetts Amherst, Amherst, Massachusetts 01003, United States.

Journal of the American Chemical Society
|March 10, 2025
PubMed
Summary
This summary is machine-generated.

This study introduces Dual-Action-Only PROTACs (DAO-PROTACs), a novel drug technology. These PROTACs require both hypoxia and cathepsin-L for activation, reducing side effects and improving safety.

More Related Videos

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.4K
A Protocol for Real-time 3D Single Particle Tracking
10:16

A Protocol for Real-time 3D Single Particle Tracking

Published on: January 3, 2018

14.8K

Related Experiment Videos

Last Updated: May 23, 2025

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.2K
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.4K
A Protocol for Real-time 3D Single Particle Tracking
10:16

A Protocol for Real-time 3D Single Particle Tracking

Published on: January 3, 2018

14.8K

Area of Science:

  • Drug Discovery and Development
  • Molecular Biology
  • Biochemistry

Background:

  • Proteolysis targeting chimeras (PROTACs) are potent pseudocatalytic drugs.
  • On-target, off-site homing of PROTACs can lead to undesirable consequences.
  • Targeted protein degradation offers a promising therapeutic strategy.

Purpose of the Study:

  • To develop a generalizable AND-logic gated PROTAC system for targeted protein degradation.
  • To design PROTAC molecules activated by dual disease-relevant endogenous stimuli.
  • To mitigate cytotoxicity associated with PROTAC-based therapies.

Main Methods:

  • Design and synthesis of Dual-Action-Only PROTAC (DAO-PROTAC) molecules.
  • Development of a dual-stimulus activation mechanism requiring hypoxia and cathepsin-L.
  • Evaluation of DAO-PROTAC activity and cytotoxicity compared to free PROTACs and single-stimulus pro-PROTACs.

Main Results:

  • DAO-PROTACs are dormant until activated by the concurrent presence of hypoxia and cathepsin-L.
  • Activation of DAO-PROTACs leads to the degradation of the protein of interest (POI).
  • DAO-PROTACs exhibit significantly reduced cytotoxicity compared to conventional PROTACs.

Conclusions:

  • DAO-PROTACs represent a novel AND-logic gated approach for precise protein degradation.
  • Dual-stimulus activation enhances the safety profile of PROTAC-based therapeutics.
  • This technology holds potential for safer and more effective targeted protein degradation therapies.